Knight Therapeutics Statistics
Total Valuation
Knight Therapeutics has a market cap or net worth of 406.28 million. The enterprise value is 332.14 million.
| Market Cap | 406.28M |
| Enterprise Value | 332.14M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | -7.80% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 86.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.97, with an EV/FCF ratio of 7.50.
| EV / Earnings | -21.42 |
| EV / Sales | 1.37 |
| EV / EBITDA | 7.97 |
| EV / EBIT | 57.78 |
| EV / FCF | 7.50 |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.41 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 1.00 |
| Debt / FCF | 0.96 |
| Interest Coverage | 0.69 |
Financial Efficiency
Return on equity (ROE) is -2.70% and return on invested capital (ROIC) is 0.59%.
| Return on Equity (ROE) | -2.70% |
| Return on Assets (ROA) | 0.51% |
| Return on Capital (ROIC) | 0.59% |
| Revenue Per Employee | 340,506 |
| Profits Per Employee | -21,391 |
| Employee Count | 725 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.17% in the last 52 weeks. The beta is 0.50, so Knight Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +23.17% |
| 50-Day Moving Average | 4.25 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 20.41 |
| Average Volume (20 Days) | 1,720 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 246.87 million and -15.51 million in losses. Loss per share was -0.15.
| Revenue | 246.87M |
| Gross Profit | 119.41M |
| Operating Income | 5.85M |
| Pretax Income | -17.31M |
| Net Income | -15.51M |
| EBITDA | 40.48M |
| EBIT | 5.85M |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 115.05 million in cash and 42.46 million in debt, giving a net cash position of 75.40 million.
| Cash & Cash Equivalents | 115.05M |
| Total Debt | 42.46M |
| Net Cash | 75.40M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 557.34M |
| Book Value Per Share | 5.50 |
| Working Capital | 186.15M |
Cash Flow
In the last 12 months, operating cash flow was 45.96 million and capital expenditures -1.65 million, giving a free cash flow of 44.31 million.
| Operating Cash Flow | 45.96M |
| Capital Expenditures | -1.65M |
| Free Cash Flow | 44.31M |
| FCF Per Share | n/a |
Margins
Gross margin is 48.37%, with operating and profit margins of 2.37% and -6.28%.
| Gross Margin | 48.37% |
| Operating Margin | 2.37% |
| Pretax Margin | -7.01% |
| Profit Margin | -6.28% |
| EBITDA Margin | 16.40% |
| EBIT Margin | 2.37% |
| FCF Margin | 17.95% |
Dividends & Yields
Knight Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 7.80% |
| Shareholder Yield | 7.80% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Knight Therapeutics has an Altman Z-Score of 2.69. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.69 |
| Piotroski F-Score | n/a |